There wasn't any investment in R and D that would justify that kind of increase.
One of the issues that really troubles me is the lack of transparency in the system.
We looked at Turing, we looked at Valeant, and what we found was a pattern of certain, what I call, hedge fund pharma co...
Last year, the Senate Aging Committee did an extensive investigation into the spiraling cost increases of certain prescr...
S. 109 has 45 bipartisan cosponsors.
opening statement
One of the committee's top priorities is to make sure that each of the intelligence agencies is doing everything that it...
I think you're absolutely right, that we have to put more effort at the front end of this problem and reduce access by c...
My question to each of you is what more do we need to do? Why are the efforts that everybody is making and working so ha...
This headline disturbed me greatly because I feel there's been so much focus on the opioid problem, the epidemic that is...
I was a very early supporter and co-sponsor of it many years ago, and I hope it will slide through the Committee, with y...